Evoke Pharma (EVOK) Stock Price, News & Analysis

Company Overview

Evoke Pharma (NASDAQ: EVOK) is a specialty biopharmaceutical company focused on the development and commercialization of treatments for gastrointestinal motility disorders. Headquartered in San Diego, California, the company concentrates its efforts on novel formulations designed to address significant unmet needs in patients suffering from delayed gastric emptying and related symptoms. Through targeted research and development, Evoke Pharma aims to bring innovative therapies to market that enhance clinical efficacy and patient quality of life.

The company’s lead product, GIMOTI® (metoclopramide) nasal spray, is approved in the United States for the acute and recurrent treatment of symptoms in adults with diabetic and idiopathic gastroparesis. GIMOTI’s unique nasal formulation allows for rapid absorption, offering an alternative to existing oral therapies that are often limited by gastrointestinal transit issues. Beyond GIMOTI, Evoke Pharma continues to explore additional proprietary formulations and delivery mechanisms to expand its pipeline and address broader gastrointestinal indications.

Founded in 2004, Evoke Pharma has evolved from early-stage research into a commercially oriented enterprise. The company completed a public listing on the NASDAQ in 2013, providing the capital necessary to advance clinical programs and scale manufacturing capabilities. Over the years, Evoke Pharma has entered strategic collaborations and licensing discussions to support international commercialization, particularly targeting markets in Europe and Asia where gastroparesis prevalence continues to rise.

Leadership at Evoke Pharma is led by President and Chief Executive Officer Peter W. Greenleaf, who brings more than two decades of pharmaceutical industry experience, including roles in commercial operations and corporate development. Supported by a seasoned management team and board of directors with deep expertise in drug development, regulatory affairs and market access, the company is well positioned to execute its mission of delivering differentiated gastrointestinal therapies to patients worldwide.

Key Stats

• Today's Range: $5.80 to $6.43
• 50-Day Range: $2.54 to $6.99
• 52-Week Range: $1.94 to $12.32
• Volume: 629,214 shs
• Average Volume: 701,562 shs
• Market Capitalization: $8.95 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

Evoke Pharma Stock Analysis - MarketRank™

Evoke Pharma scored higher than 17% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: N/A
• Analyst Rating: N/A

Consensus Rating

There is not enough analysis data for Evoke Pharma.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: N/A

Price to Earnings Ratio vs. the Market

The P/E ratio of Evoke Pharma is -2.09, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Evoke Pharma is -2.09, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Evoke Pharma has a P/B Ratio of 1.27. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 5.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

0.84% of the float of Evoke Pharma has been sold short.

Short Interest Ratio / Days to Cover

Evoke Pharma has a short interest ratio ("days to cover") of 0, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Evoke Pharma has recently decreased by 33.33%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Evoke Pharma does not currently pay a dividend.

Dividend Growth

Evoke Pharma does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

0.84% of the float of Evoke Pharma has been sold short.

Short Interest Ratio / Days to Cover

Evoke Pharma has a short interest ratio ("days to cover") of 0, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Evoke Pharma has recently decreased by 33.33%, indicating that investor sentiment is improving significantly.

News and Social Media

• Score: 3.1 / 5
• News Sentiment: 0.50

News Sentiment

Evoke Pharma has a news sentiment score of 0.50. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.99 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 5 news articles for Evoke Pharma this week, compared to 1 article on an average week.

Search Interest

3 people have searched for EVOK on MarketBeat in the last 30 days.

MarketBeat Follows

1 people have added Evoke Pharma to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 0.0 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Evoke Pharma insiders have not sold or bought any company stock.

Percentage Held by Insiders

Only 2.29% of the stock of Evoke Pharma is held by insiders.

EVOK Stock Analysis - Frequently Asked Questions

How have EVOK shares performed this year?

Evoke Pharma's stock was trading at $4.42 at the beginning of the year. Since then, EVOK stock has increased by 36.0% and is now trading at $6.01.

How were Evoke Pharma's earnings last quarter?

Evoke Pharma, Inc. (NASDAQ:EVOK) posted its quarterly earnings data on Monday, May, 12th. The specialty pharmaceutical company reported ($0.51) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.33) by $0.18. The specialty pharmaceutical company had revenue of $3.08 million for the quarter, compared to analyst estimates of $3.32 million. Evoke Pharma had a negative trailing twelve-month return on equity of 101.91% and a negative net margin of 43.80%.

When did Evoke Pharma's stock split?

Evoke Pharma's stock reverse split on Thursday, August 1st 2024.The 1-12 reverse split was announced on Thursday, August 1st 2024. The number of shares owned by shareholders was adjusted after the market closes on Thursday, August 1st 2024. An investor that had 100 shares of stock prior to the reverse split would have 8 shares after the split.

How do I buy shares of Evoke Pharma?

Shares of EVOK stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Evoke Pharma own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Evoke Pharma investors own include BMO Capital Markets (), Stifel Nicolaus (), Wunderlich (), Standpoint Research (), Duncan Williams (), Soleil Securities () and Sterne Agee CRT ().

Company Calendar

• Last Earnings: 5/12/2025
• Today: 7/12/2025
• Next Earnings (Estimated): 8/11/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - GENERIC DRG
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:EVOK
• CIK: 1403708
• Web: www.evokepharma.com
• Phone: (858) 345-1494
• Fax: N/A
• Employees: 4
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): ($2.87)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$5.35 million
• Net Margins: -43.80%
• Pretax Margin: -43.80%
• Return on Equity: -101.91%
• Return on Assets: -33.75%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 1.55
• Quick Ratio: 1.50

Sales & Book Value

• Annual Sales: $10.25 million
• Price / Sales: 0.87
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $4.74 per share
• Price / Book: 1.27

Miscellaneous

• Outstanding Shares: 1,490,000
• Free Float: 1,459,000
• Market Cap: $8.95 million
• Optionable: Not Optionable
• Beta: -0.04